Skip to main content
Pharmadrug Inc. logo

Pharmadrug Inc. — Investor Relations & Filings

Ticker · PHRX ISIN · CA71716W2040 LEI · 529900PHQPAWL5ITEB39 CSE Manufacturing
Open in API
Filings indexed 151 across all filing types
Latest filing 2026-01-06 Regulatory Filings
Country CA Canada
Listing CSE PHRX

About Pharmadrug Inc.

https://pharmadrug.ca/

Pharmadrug Inc. is a specialty pharmaceutical company focused on the research, development, and commercialization of controlled-substances and natural medicines. The company's primary focus areas include the clinical development of reformulated natural-based medicines aimed at treating unmet needs in oncology and infectious diseases. Additionally, Pharmadrug develops synthetic and biosynthetic formulations of existing drugs, specifically addressing opportunities related to the potential third wave of drug policy reform concerning controlled substances.

Recent filings

Filing Released Lang Actions
Material change report - English.pdf
Regulatory Filings Classification · 87% confidence The document is a Canadian Form 51-102F3 Material Change Report filed on SEDAR+, detailing a corporate transaction (acquisition of Canurta units), share issuance, debt restructuring and early warning disclosure. It is a formal regulatory filing rather than an earnings release, investor presentation, or share issue notice alone. No specific category for Canadian material change reports exists in the taxonomy, so it falls under the fallback “Regulatory Filings” category.
2026-01-06 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a 'Form 52-109FV2', which is a standard Canadian regulatory certification for interim filings. It is a standalone certification document signed by the CFO, confirming the accuracy of the interim financial report and MD&A. Since it is a regulatory certification document rather than the financial report itself, and it does not fit into specific categories like 'Annual Report' or 'Interim Report', it is classified as a Regulatory Filing.
2025-11-24 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a 'Certification of Interim Filings' (Form 52-109FV2) for a venture issuer. This is a regulatory requirement accompanying interim financial reports to certify the accuracy of the filings. Since it is a standalone regulatory certification document rather than the financial report itself, and it does not fit into specific categories like 'Annual Report' or 'Interim Report', it falls under the 'Regulatory Filings' category.
2025-11-24 English
Interim MD&A - English.pdf
Management Reports Classification · 100% confidence The document is titled 'Management's Discussion and Analysis' (MD&A) for the three and nine months ended September 30, 2025 and 2024. It provides a detailed narrative explanation of the company's business operations, clinical trial progress, patent status, and strategic developments (such as the acquisition of Canurta). This document is a standard management report accompanying financial statements, which falls under the 'Management Reports' category.
2025-11-24 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS' for the three and nine months ended September 30, 2025. It contains comprehensive financial statements (Statement of Financial Position, Statement of Loss and Comprehensive Loss, Statement of Cash Flows, and Statement of Changes in Shareholders' Equity) along with detailed explanatory notes. This meets the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. 9M 2025
2025-11-24 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a Pricing Supplement to a Short Form Base Shelf Prospectus outlining the terms of a debt securities issuance by Royal Bank of Canada (RBC). It details the offering size, pricing, interest and redemption features of the new series of contingent yield senior notes, which is clearly a capital raising/financing activity. It is not a share issuance under equity (so SHA is not appropriate), but it is a financing update. Therefore, it fits the Capital/Financing Update category.
2025-07-30 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.